Targeted Immunotherapy for Autoimmune Disease
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
In the past few decades, biological drugs and small molecule inhibitors targeting inflammatory cytokines, immune cells, and intracellular kinases have become the standard-of-care to treat autoimmune diseases. Inhibition of TNF, IL-6, IL-17, and IL-23 has revolutionized the treatment of autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis. B cell depletion therapy using anti-CD20 mAbs has shown promising results in patients with neuroinflammatory diseases, and inhibition of B cell survival factors is approved for treatment of systemic lupus erythematosus. Targeting co-stimulatory molecules expressed on Ag-presenting cells and T cells is also expected to have therapeutic potential in autoimmune diseases by modulating T cell function. Recently, small molecule kinase inhibitors targeting the JAK family, which is responsible for signal transduction from multiple receptors, have garnered great interest in the field of autoimmune and hematologic diseases. However, there are still unmet medical needs in terms of therapeutic efficacy and safety profiles. Emerging therapies aim to induce immune tolerance without compromising immune function, using advanced molecular engineering techniques.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 3×
“Depending on the dose of Ag, low doses of Ag promote the generation of Treg cells secreting IL-4, IL-10, and TGF-β, whereas high doses of Ag promote the clonal deletion or anergy of specific T cells (125).”
BackgroundIL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · cited 1×
“Subsequently, IL-23 stabilizes pathogenic Th17 cells for proliferation and survival (70).”
BackgroundCar t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · cited 1×
“Following therapeutic success in a patient with diffuse large B cell lymphoma, CD19 CAR T cell therapy was approved for treatment of B-cell lymphoma and acute lymphoblastic leukemia (114).”
BackgroundEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623 · cited 1×
“Ab-independent functions of B cells explain the treatment efficacy of B cell depletion therapies in RA and MS despite the absence of autoantibody reduction (88,89).”
BackgroundInterleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · cited 1×
“Dimerization of gp130 sequentially activates multiple signaling pathways including JAKSTAT, MAPK, PI3K, and YES-associated protein 1, which translocates to the nucleus and controls the transcription of genes associated with cell growth, proliferation, and inflammation (61,62).”
BackgroundThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
The IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443 · cited 1×
“In the physiological state, Th17 cells contribute to innate immunity by recruiting neutrophils, host defense against bacteria and fungi, and tissue repair at skin and mucosal sites (66,67).”
BackgroundCTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233 · cited 4×
“Based on counter-regulation of CD28 and CTLA-4, a fusion protein composed of extracellular domain of CTLA4 and an IgG Fc region (CTLA4-Ig) was developed to inhibit CD28 signaling by occupying CD80 and CD86.”
BackgroundInfluentialMechanisms and consequences of Jak–STAT signaling in the immune system
Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221
Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity
Mantovani, A., Dinarello, C. A., Molgora, M., & Garlanda, C. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.012 · Cited by 1,046 · cited 1×
“Upon occupation by IL-1α or IL-1β, IL-1R1 forms a heterotrimeric complex with IL-1R3 to recruit myeloid differentiation primary response gene 88 (MYD88), which triggers a subsequent kinase cascade (IL-1R-associated kinases [IRAKs], IκB kinase, IκB, and NF-κB) that promotes a pro-inflammatory state (47,50).”
BackgroundCD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937 · cited 1×
“CD28 signaling is a well-known co-stimulatory pathway for T cell activation and differentiation through activation of the MAPK, AKT, and NF-κB pathways (97).”
BackgroundCree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756 · cited 1×
“A humanized anti-CD19 mAb, inebilizumab, was approved for neuromyelitis optica spectrum disorder (92) and is undergoing clinical trials to treat other inflammatory neurological disorders (Table 2).”
BackgroundGabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., Klearman, M., Musselman, D., Agarwal, S., Green, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60250-0 · Cited by 672
Pharmacological Inhibitors of the NLRP3 Inflammasome
Zahid, A., Li, B., Kombe, A. J. K., Jin, T., & Tao, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02538 · Cited by 671 · cited 1×
“As a new therapeutic approach to inhibit IL-1 signaling, oral NLRP3 inhibitors, including dapansutrile (OLT177), are under investigation (51).”
BackgroundInterleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643 · cited 2×
“Thus, anti-IL6 mAbs, anti-IL-6R mAbs, and JAK inhibitors have been used to block IL-6 signaling, and the potential for using soluble gp130 to inhibit the IL-6/IL-6R complex is under investigation (60).”
BackgroundMethodBiology and regulation of IL-2: from molecular mechanisms to human therapy
Spolski, R., Li, P., & Leonard, W. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0046-y · Cited by 637
A gp130–Src–YAP module links inflammation to epithelial regeneration
Taniguchi, K., Wu, L.-W., Grivennikov, S. I., de Jong, P. R., Lian, I., Yu, F.-X., Wang, K., Ho, S. B., Boland, B. S., Chang, J. T., et al. (2015) · Nature · doi:10.1038/nature14228 · Cited by 633
Qian, Y., Liu, C., Hartupee, J., Altuntas, C. Z., Gulen, M. F., Jane-wit, D., Xiao, J., Lu, Y., Giltiay, N., Liu, J., et al. (2007) · Nature Immunology · doi:10.1038/ni1439 · Cited by 614 · cited 1×
“Upon binding with IL-17A, a unique intracellular cytoplasmic domain termed SEF/IL-17R of IL-17R subunit A (IL17RA) and subunit C (IL-17RC) recruit the adaptor protein Act1, which triggers ubiquitination of TNF-receptor associated factor (TRAF) 6 and subsequent activation of the NF-κB, MAPK, and activator protein 1 (AP…”
BackgroundThe multiple pathways to autoimmunity
Theofilopoulos, A. N., Kono, D. H., & Baccala, R. (2017) · Nature Immunology · doi:10.1038/ni.3731 · Cited by 590
Guttman-Yassky, E., Teixeira, H. D., Simpson, E. L., Papp, K. A., Pangan, A. L., Blauvelt, A., Thaçi, D., Chu, C.-Y., Hong, H. C.-H., Katoh, N., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00588-2 · Cited by 583
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
Krienke, C., Kolb, L., Diken, E., Streuber, M., Kirchhoff, S., Bukur, T., Akilli-Öztürk, Ö., Kranz, L. M., Berger, H., Petschenka, J., et al. (2021) · Science · doi:10.1126/science.aay3638 · Cited by 520 · cited 1×
“(130) reported successful induction of immune tolerance with a noninflammatory mRNA-based vaccine in mice model of experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein (MOG35-55).”
BackgroundRecent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
Kinase inhibition in autoimmunity and inflammation
Zarrin, A. A., Bao, K., Lupardus, P., & Vucic, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0082-8 · Cited by 431 · cited 5×
“Blockade of convergent signals by small molecule kinase inhibitors is of great interest in terms of therapeutic efficacy and long-term safety (4,5).”
BackgroundInfluentialReich, K., Teixeira, H. D., de Bruin-Weller, M., Bieber, T., Soong, W., Kabashima, K., Werfel, T., Zeng, J., Huang, X., Hu, X., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00589-4 · Cited by 402 · cited 1×
“Target kinases Structure Drug Clinical application Under investigation (phase IIb or III) JAK JAK1/3 inhibitor Tofacitinib RA JIA (31) (NCT01500551, NCT03000439) PsA AS (32) UC JAK 1/2 inhibitor Baricitinib RA SLE (NCT03843125, NCT03616912, NCT03616964) JIA (NCT03773965, NCT03773978) sJIA (NCT04088396) Atopic dermatit…”
BackgroundZhang, C., Zhang, M., Qiu, W., Ma, H., Zhang, X., Zhu, Z., Yang, C.-S., Jia, D., Zhang, T.-X., Yuan, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30070-3 · Cited by 287 · cited 2×
“Recently, therapeutic application of anti-IL-6 therapy has been investigated in SLE, neuromyelitis optica, and systemic sclerosis (17,57,58).”
BackgroundGenovese, M. C., Greenwald, M., Cho, C., Berman, A., Jin, L., Cameron, G. S., Benichou, O., Xie, L., Braun, D., Berclaz, P., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38617 · Cited by 211 · cited 1×
“Unexpectedly, this approach failed to show remarkable clinical efficacy in patients with RA, a Th17-dependent disease (75).”
BackgroundReich, D. S., Arnold, D. L., Vermersch, P., Bar-Or, A., Fox, R. J., Matta, A., Turner, T., Wallström, E., Zhang, X., Mareš, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00237-4 · Cited by 204 · cited 1×
“Some recent phase II trials with BTK inhibitors showed promising results in patients with relapsing MS (111,112).”
BackgroundMaitra, A., Shen, F., Hanel, W., Mossman, K., Tocker, J., Swart, D., & Gaffen, S. L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611589104 · Cited by 165 · cited 1×
“Upon binding with IL-17A, a unique intracellular cytoplasmic domain termed SEF/IL-17R of IL-17R subunit A (IL17RA) and subunit C (IL-17RC) recruit the adaptor protein Act1, which triggers ubiquitination of TNF-receptor associated factor (TRAF) 6 and subsequent activation of the NF-κB, MAPK, and activator protein 1 (AP…”
Background
Cited by
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Sheikhi, K., Ghaderi, S., Firouzi, H., Rahimibarghani, S., Shabani, E., Afkhami, H., & Yarahmadi, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1517369 · Cited by 20
Metadata
- Authors
- Jung, S. M., & Kim, W.-U.
- Venue
- Immune Network
- Publisher
- XMLink
- Published
- 2022
- Volume
- 22
- Issue
- 1
- Pages
- e9-e9
- ISSN
- 1598-2629 (ISSN-L)
- 2092-6685
- OpenAlex
- W4214882763
- Cited by
- 171
- References
- 28
- FWCI
- 10.70
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.